Get 30% off on all global market reports with code ONLINE30 – stay updated on tariff changes, macroeconomic trends, and more!
How Has the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Shifted in Recent Years?
In recent times, the market for chronic inflammatory demyelinating polyneuropathy (cidp) has seen significant growth. The market value is predicted to rise from $2.1 billion in 2024 to $2.27 billion in 2025, representing a compound annual growth rate (CAGR) of 8.1%. The marked growth in the historical period can be attributed to factors such as a surge in the elderly population, enhanced treatment options, heightened awareness leading to early diagnosis, progress in immunology and autoimmune research, and the escalating incidence of autoimmune diseases.
In the coming years, the market size for chronic inflammatory demyelinating polyneuropathy (cidp) is projected to experience robust growth, and is poised to reach $3.09 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%. The progression during the predicted period is credited to a globally aging demographic, an elevated concentration on uncommon ailments and autoimmune conditions, enhanced healthcare availability, campaigns promoting patient advocacy and awareness, as well as an upgraded healthcare infrastructure. The forecast period is set to witness rising incidence rates of chronic inflammatory demyelinating polyneuropathy, advances in therapeutic interventions, augmented research and developmental activities, the introduction of biosimilar therapies, and the progression of tailored medical treatments as key market dynamics.
Claim Your Free Sample Report:
http://www.thebusinessresearchcompany.com/sample….p;type=smp
What’s Driving the Upward Growth Trajectory of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
The growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market is anticipated to be fueled by the escalating expenditure in healthcare. Such expenditure is trending upwards due to amplified investments in medical facilities, a growing need for progressive treatments, broader insurance coverage, and governmental initiatives to improve the accessibility of healthcare services. A higher spending on healthcare allows for greater accessibility to innovative treatments, quicker diagnosis, and effective management of CIDP, thereby enhancing patient outcomes and their quality of life. For example, in May 2024, as reported by the UK-based government department, Office for National Statistics, the total expenditure on healthcare recorded a notable acceleration with a 5.6% increase in nominal terms from 2022 to 2023.
This was a substantial increase compared to the growth of just 0.9% seen in 2022. Hence, the escalating expenditure on healthcare is propelling the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market.
Which Segments in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry Are Seeing the Fastest Growth?
The chronic inflammatory demyelinating polyneuropathy (cidp)market covered in this report is segmented –
1) By Treatment: Intravenous Immunoglobulin; Corticosteroids; Plasmapheresis; Physiotherapy; Other Treatments
2) By Route Of Administration: Intravenous; Oral; Other Routes Of Administration
3) By Diagnosis: Electrodiagnostic Testing; Nerve Conduction; Electromyography (EMG); Spinal Fluid Analysis; Other Diagnosis
4) By Distribution Channel: Hospitals; Pharmacies; Online Pharmacies; Specialty Clinics
5) By End User: Hospitals; Research Institutions; Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy; High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids; Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis; Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises; Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents; Monoclonal Antibodies
Access the Full Report Today:
http://www.thebusinessresearchcompany.com/report/…ket-report
How Will Shifting Market Trends Influence Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) System Adoption?
Significant players in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are concentrating on developing methods such as intravenous immunoglobulin (IVIG) therapy to boost the effectiveness of treatments, enhance patient results, and offer more precise and effective immune system modulation for CIDP management. IVIG therapy involves using concentrated antibodies from healthy individuals to help regulate the immune system and minimize inflammation in autoimmune disorders. For example, in January 2024, Takeda Pharmaceutical Company Limited, which is based in Japan and specializes in biopharmaceuticals, received FDA approval for GAMMAGARD LIQUID for use as an IVIG therapy in adults suffering from chronic inflammatory demyelinating polyneuropathy (CIDP). This endorsement allows it to be used as induction therapy, starting with an initial dosage and followed by maintenance dosages for long-term disease control and improving neuromuscular function.
Which Global Regions Are Powering Demand in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get a Customized Version of the Report:
http://www.thebusinessresearchcompany.com/customi…p;type=smp
How Key Players Are Driving Growth in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Major companies operating in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Cipla Inc., Hikma Pharmaceuticals plc, Halozyme Therapeutics, Hualan Biological Engineering Inc, argenx SE, Hovione, Nihon Pharmaceutical Co. Ltd., Bio Products Laboratory Ltd., AdvaCare Pharma.
Access the Complete Report:
http://www.thebusinessresearchcompany.com/purchas…x?id=21144
How Our Market Research Reports Help Maximize ROI Across Industries:
* Identify High-Growth Opportunities: Pinpoint emerging trends, untapped segments, and regional hotspots that align with your strategic goals.
* Reduce Investment Risk: Make data-driven decisions with confidence by understanding market dynamics, key drivers, and competitive threats.
* Optimize Strategic Planning: Align your product development, marketing, and expansion plans with industry forecasts and customer behaviour insights.
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
News From
The Business Research Company …
Category: Industry Reports & Market Analysis Profile: The Business Research Company is a leading market research and consulting services provider. It offers over 9,500 market reports across 27 industries in 60+ geographies, providing detailed insights and forecasts. Its customised research solutions support companies in making critical decisions, while its continuous research service enhances organizational capabilities. The flagship Global Market Model database provides comprehensive market intelligence with 1,500,000 datasets covering 8,000+ mark …
This email address is being protected from spambots. You need JavaScript enabled to view it.
